Standout Papers

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Po... 2010 2026 2015 2020 443
  1. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer (2010)
    Angelo Di Leo, Guy Jérusalem et al. Journal of Clinical Oncology

Immediate Impact

10 by Nobel laureates 5 from Science/Nature 93 standout
Sub-graph 1 of 19

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
2 intermediate papers

Works of Sally Garnett being referenced

A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
2013

Author Peers

Author Last Decade Papers Cites
Sally Garnett 601 534 336 12 830
Roberto Torres 558 523 298 20 781
И А Смирнова 566 507 280 15 800
William N. Harwin 475 255 526 21 837
Lauren Brusco 332 222 222 17 795
Joseph J. Stephenson 418 333 156 13 868
M. Azab 537 226 386 7 831
Addie Dvir 325 367 176 25 778
Jill Knox 459 198 441 10 864
Claude El Kouri 495 484 203 19 880
Seta Shahin 794 315 95 13 925

All Works

Loading papers...

Rankless by CCL
2026